Accuitive Medical Ventures

Accuitive Medical Ventures (AMV) is a Duluth, Georgia-based venture capital firm founded in 2003, focused exclusively on early-stage medical device and healthcare technology investments. With $230 million in committed capital and offices in Palo Alto, Atlanta, Rochester, and Fernandina Beach, AMV is led by six managing directors: Gerard van Hamel Platerink, John Deedrick, Charlie Larsen, Mike Partsch, Steve Waite, and Tom Weldon. The firm invests $1 million to $10 million at seed through Series B stages, leading rounds across a portfolio of 86 companies. The portfolio has produced 3 IPOs and 10 acquisitions. Inogen, a portable oxygen concentrator company, listed on NASDAQ at a market cap of $70.6 million. NeuroStar, a transcranial magnetic stimulation device maker, IPO'd on NASDAQ in June 2018 at a $285 million valuation. Nevro, a spinal cord stimulation company, was acquired by Globus Medical in February 2025 for $250 million. Additional portfolio companies include POGO Automatic, AcuFocus (exited January 2023), and Sebacia. AMV takes a market-driven approach to investment, identifying revolutionary medical device and technology opportunities where clinical need is large and the path to reimbursement is clear. The firm's six-managing-director structure reflects deep specialization across cardiac, orthopedic, neurological, and ophthalmic device categories. Active board participation from managing directors with direct medical device operating experience distinguishes AMV's model from generalist healthcare VCs, providing founders with investors who understand the clinical, regulatory, and commercial complexities of device development from product conception through exit.